Apomorphine for Erectile Dysfunction
Apomorphine is not recommended as a first-line treatment for erectile dysfunction due to its limited efficacy compared to PDE-5 inhibitors and is no longer widely available in many countries. 1, 2
Mechanism of Action
Apomorphine is a dopamine agonist that acts on central nervous system areas involved in erectile function:
- Primarily activates dopamine D1 and D2 receptors 3
- Induces selective activation in the nucleus paraventricularis, leading to erectogenic signals 4
- Works through central mechanisms rather than directly affecting penile blood flow
Efficacy
Apomorphine has demonstrated modest efficacy in clinical trials:
- Sublingual formulation (2-3 mg) showed improvement in erections firm enough for intercourse in 39-49% of attempts compared to 13-24% at baseline 5, 4
- Average median time to erection was approximately 18-23 minutes 5, 4
- Response rates vary significantly based on the severity and etiology of ED:
Comparison to PDE-5 Inhibitors
The American College of Physicians strongly recommends PDE-5 inhibitors as first-line therapy for ED based on high-quality evidence 1:
- Sildenafil was more effective than apomorphine in improving erectile function and successful intercourse attempts 1
- PDE-5 inhibitors demonstrate superior efficacy (73-88% improvement in erections vs. 39-49% for apomorphine) 1, 5, 4
Safety Profile
Apomorphine's side effect profile includes:
- Nausea (most common side effect, 8-12% of patients) which tends to diminish with continued use 5, 4, 6
- Vasovagal syncope (rare, <0.2% of patients) preceded by prodromal symptoms 4
- Generally well-tolerated with few drug interactions 6
Current Status and Availability
- Apomorphine is no longer widely available in Western countries for ED treatment 2
- The American Urological Association does not include apomorphine in its current guidelines for ED management 7, 8
Clinical Considerations
Apomorphine might be considered in very specific situations:
- For patients with contraindications to PDE-5 inhibitors (e.g., nitrate therapy)
- For patients who have failed or are intolerant to established ED treatments 2
- When a central mechanism of action is specifically desired
Conclusion
Based on current evidence and guidelines, apomorphine has a very limited role in modern ED management. The American College of Physicians and American Urological Association both recommend PDE-5 inhibitors as first-line therapy for erectile dysfunction due to their superior efficacy and favorable risk-benefit profile 1, 7, 8.